Search
                    Cyclophosphamide Treatment Options in San Jose, CA
A collection of 20 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the San Jose, CA. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
            13 - 20 of 20
        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy, such as fluorouracil, epirubicin, cyclophosphamide, and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating breast cancer.
PURPOSE: This randomized phase III trial is studying two combination chemotherapy regimens to compare how well they work in treating women who have undergone surgery for breast cancer that has not spre...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                08/10/2022
            
            Locations: Alta Bates Summit Comprehensive Cancer Center, Berkeley, California  +50 locations         
        
        
            Conditions: Breast Cancer
        
            
        
    
                
                                    A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
                                
            
            
        Completed
                            
            
                This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant therapy in participants with human epidermal growth (HER) factor 2 (HER2)-positive primary invasive breast cancer. Following surgery and anthracycline-based chemotherapy, participants will receive either trastuzumab emtansine at a dose of 3.6 milligrams per kilogram (mg/kg)...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/13/2022
            
            Locations: Kaiser Permanente - Oakland, Oakland, California  +10 locations         
        
        
            Conditions: Breast Cancer
        
            
        
    
                
                                    A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
                                
            
            
        Completed
                            
            
                The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this stud...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                04/13/2022
            
            Locations: Central Hematology/Oncology Medical Group, Inc., Alhambra, California  +49 locations         
        
        
            Conditions: Breast Cancer
        
            
        
    
                
                                    Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
                                
            
            
        Unknown
                            
            
                RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                04/13/2022
            
            Locations: Kaiser Anaheim Medical Center, Anaheim, California  +66 locations         
        
        
            Conditions: Breast Cancer
        
            
        
    
                
                                    Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
                                
            
            
        Completed
                            
            
                This trial combines dose dense chemotherapy with doxorubicin and cyclophosphamide (AC) followed by standard, every 3 week docetaxel and GW572016 (lapatinib) for neoadjuvant treatment of Her2neu positive stage II/III breast cancer. The purpose of the study was to determine whether lapatinib combined with chemotherapy was safe and resulted in an increase in pathologic complete response rates.             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                11/28/2017
            
            Locations: Santa Clara Valley Medical Center, San Jose, California  +1 locations         
        
        
            Conditions: Breast Cancer, Metastatic Breast Cancer
        
            
        
    
                
                                    Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
                                
            
            
        Unknown
                            
            
                RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the g...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 120 years
            Trial Updated:
                09/12/2017
            
            Locations: East Bay Radiation Oncology Center, Castro Valley, California  +38 locations         
        
        
            Conditions: Breast Cancer
        
            
        
    
                
                                    Treatment With Pazopanib for Neoadjuvant Breast Cancer
                                
            
            
        Completed
                            
            
                The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a pathological complete response in females with breast cancer.             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                01/30/2014
            
            Locations: GSK Investigational Site, Antioch, California  +18 locations         
        
        
            Conditions: Neoplasms, Breast
        
            
        
    
                
                                    S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one chemotherapy drug may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving cyclophosphamide together with capecitabine works in treating women with stage IV breast cancer.             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                07/03/2013
            
            Locations: Eden Medical Center, Castro Valley, California  +24 locations         
        
        
            Conditions: Breast Cancer
        
            
        
    13 - 20 of 20
            